A Humanizing Rewrite for CAR T Cells in Autoimmune Disease: A StepToward Repeatable, Durable Therapy

1. Peng, B. J. et al. Preclinical specificity & activity of a fully human 4-1BB-expressing anti-CD19 CAR therapy for treatment-resistant autoimmune disease. Mol. Ther. Methods Clin. Dev. 32, 140–151 (2024).

2. Hayter, S. M. & Cook, M. C. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun. Rev. 11, 754–765 (2012).

3. Davidson, A. & Diamond, B. Autoimmune diseases. N. Engl. J. Med. 345, 340–350 (2001).

4. Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222–233 (2010).

5. Roll, P. et al. Regeneration of B cell subsets after rituximab treatment in patients with rheumatoid arthritis. Arthritis Rheum. 58, 598–604 (2008).

6. Gill, S. & June, C. H. Going viral: chimeric antigen receptor T-cell therapy for hematologic malignancies. Immunol. Rev. 263, 68–89 (2015).

7. Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. N. Engl. J. Med. 387, 2030–2038 (2022).

8. Mougiakakos, D. et al. CD19-targeted CAR T cells in autoimmune disease. Nat. Med. 29, 115–123 (2023).

9. Maus, M. V., Grupp, S. A., Porter, D. L. & June, C. H. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625–2635 (2014).

10. Brudno, J. N. & Kochenderfer, J. N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15, 31–46 (2018).

11. Hale, M. et al. Engineering CAR-T cells with a fully human scFv to reduce immunogenicity in cancer and autoimmune disease. Mol. Ther. 30, 1341–1353 (2022).

12. Sommermeyer, D. et al. Fully human anti-CD19 CAR T cells for the treatment of B cell malignancies and autoimmune disease. Blood 127, 2081–2090 (2016).